GSK plc (NYSE:GSK) Shares Bought by Advisors Management Group Inc. ADV

Advisors Management Group Inc. ADV increased its position in shares of GSK plc (NYSE:GSK) by 4.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 86,271 shares of the pharmaceutical company’s stock after purchasing an additional 3,824 shares during the quarter. Advisors Management Group Inc. ADV’s holdings in GSK were worth $3,527,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. 1832 Asset Management L.P. lifted its holdings in GSK by 9.1% in the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock worth $132,000 after acquiring an additional 257 shares during the last quarter. Boltwood Capital Management raised its holdings in GSK by 2.5% during the 2nd quarter. Boltwood Capital Management now owns 11,133 shares of the pharmaceutical company’s stock worth $429,000 after buying an additional 270 shares during the period. First Affirmative Financial Network boosted its position in GSK by 4.7% during the 2nd quarter. First Affirmative Financial Network now owns 6,359 shares of the pharmaceutical company’s stock worth $245,000 after acquiring an additional 283 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock worth $137,000 after acquiring an additional 303 shares during the last quarter. Finally, International Assets Investment Management LLC raised its position in GSK by 6.3% during the second quarter. International Assets Investment Management LLC now owns 5,535 shares of the pharmaceutical company’s stock valued at $213,000 after acquiring an additional 327 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Price Performance

NYSE:GSK opened at $35.90 on Thursday. The company has a fifty day moving average price of $40.25 and a 200 day moving average price of $40.97. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The stock has a market cap of $74.39 billion, a P/E ratio of 23.31, a PEG ratio of 1.42 and a beta of 0.66. GSK plc has a one year low of $33.89 and a one year high of $45.92.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be given a $0.3928 dividend. This represents a $1.57 annualized dividend and a yield of 4.38%. The ex-dividend date is Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is 100.00%.

Analyst Ratings Changes

GSK has been the subject of a number of recent analyst reports. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.00.

Insider Buying and Selling at GSK

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 10.00% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.